The long, expensive and often ineffective drug development process is ripe for innovation. 14 of the 50 FDA approved drugs last year went through an accelerated pathway proving that we can solve for speed, but moving to new pricing mechanisms will be the true challenge. Can we utilize new R&D models, technology and clinical trial processes to curb the graph from going even further up and to the right? These three biopharma mavens each have their own ideas of how to create a future where new therapies are developed fast, priced fairly and achieve high efficacy for all patients in need. Challenge accepted!
